5-132604928-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_005732.4(RAD50):c.2647C>T(p.Arg883Cys) variant causes a missense change. The variant allele was found at a frequency of 0.000317 in 1,613,882 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00036 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00031 ( 3 hom. )
Consequence
RAD50
NM_005732.4 missense
NM_005732.4 missense
Scores
6
11
Clinical Significance
Conservation
PhyloP100: 3.64
Genes affected
RAD50 (HGNC:9816): (RAD50 double strand break repair protein) The protein encoded by this gene is highly similar to Saccharomyces cerevisiae Rad50, a protein involved in DNA double-strand break repair. This protein forms a complex with MRE11 and NBS1. The protein complex binds to DNA and displays numerous enzymatic activities that are required for nonhomologous joining of DNA ends. This protein, cooperating with its partners, is important for DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination. Knockout studies of the mouse homolog suggest this gene is essential for cell growth and viability. Mutations in this gene are the cause of Nijmegen breakage syndrome-like disorder.[provided by RefSeq, Apr 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -9 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.00614956).
BP6
Variant 5-132604928-C-T is Benign according to our data. Variant chr5-132604928-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 128008.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=2, not_provided=1, Benign=2}.
BS2
High Homozygotes in GnomAdExome4 at 3 AD,AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RAD50 | NM_005732.4 | c.2647C>T | p.Arg883Cys | missense_variant | 16/25 | ENST00000378823.8 | NP_005723.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD50 | ENST00000378823.8 | c.2647C>T | p.Arg883Cys | missense_variant | 16/25 | 1 | NM_005732.4 | ENSP00000368100.4 | ||
ENSG00000283782 | ENST00000640655.2 | c.2350C>T | p.Arg784Cys | missense_variant | 17/26 | 5 | ENSP00000491596.2 |
Frequencies
GnomAD3 genomes AF: 0.000361 AC: 55AN: 152178Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
55
AN:
152178
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000577 AC: 145AN: 251140Hom.: 1 AF XY: 0.000707 AC XY: 96AN XY: 135744
GnomAD3 exomes
AF:
AC:
145
AN:
251140
Hom.:
AF XY:
AC XY:
96
AN XY:
135744
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000313 AC: 457AN: 1461586Hom.: 3 Cov.: 31 AF XY: 0.000333 AC XY: 242AN XY: 727082
GnomAD4 exome
AF:
AC:
457
AN:
1461586
Hom.:
Cov.:
31
AF XY:
AC XY:
242
AN XY:
727082
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000361 AC: 55AN: 152296Hom.: 0 Cov.: 32 AF XY: 0.000443 AC XY: 33AN XY: 74468
GnomAD4 genome
AF:
AC:
55
AN:
152296
Hom.:
Cov.:
32
AF XY:
AC XY:
33
AN XY:
74468
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
7
ExAC
AF:
AC:
68
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:5Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Nijmegen breakage syndrome-like disorder Uncertain:1Benign:1Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Benign and reported on 06-27-2019 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 23, 2017 | - - |
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | May 12, 2021 | - - |
not provided Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jun 09, 2022 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; Variants in candidate genes are classified as variants of uncertain significance in accordance with ACMG guidelines (Richards et al., 2015) - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The RAD50 p.Arg883Cys variant was identified in the literature however the frequency of this variant in an affected population was not provided. The variant was also identified in dbSNP (ID: rs138749920) as Uncertain Significance and likely Benign, ClinVar (Reported as Likely Benign by Ambry in 2018, Likely benign by Invitae in 2017, Uncertain significance by Fulgent in 2017, Uncertain significance by GeneDx in 2014), Clinvitae (Likely benign [Invitae], Uncertain significance [ClinVar]), databases. The variant was not identified in Cosmic or LOVD 3.0, databases. The variant was identified in control databases in 152 of 282540 chromosomes (1 homozygous) at a frequency of 0.000538 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Ashkenazi Jewish in 82 of 10366 chromosomes (freq: 0.00791), South Asian in 29 of 30584 chromosomes (freq: 0.000948), Other in 5 of 7206 chromosomes (freq: 0.000694), Latino in 12 of 35384 chromosomes (freq: 0.000339), European (non-Finnish) in 21 of 128990 chromosomes (freq: 0.000163), African in 2 of 24956 chromosomes (freq: 0.00008), East Asian in 1 of 19950 chromosomes (freq: 0.00005), while the variant was not observed in the and European (Finnish) populations. The p.Arg883C variant was reported as a variant of uncertain significance in a population of 278 BRCA1/2 negative patients with early onset breast cancer who received sequencing of 22 cancer susceptibility genes (Maxwell_2015_PMID: 25503501). The p.Arg883Cys variant was also reported as a variant of uncertain significance in a population of 1040 cancer patients who received germline analysis of 76 cancer predisposition genes (Mandelker_2017_PMID: 23555315). The p.Arg883Cys variant was also identified through genotyping 191,032 common and rare non-synonymous, splice site, or nonsense variants in a multiethnic sample of 2,984 breast cancer cases, 4,376 prostate cancer cases, and 7,545 controls (Haiman_2013_PMID: 23555315). The p.Arg883Cys variant was not found to be significantly associated with breast or prostate cancer (Haiman_2013_PMID: 23555315). The p.Arg883 residue is conserved in mammals but not in more distantly related organisms, and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the R variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. References Haiman CA et al. Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLoS Genet. 2013 Mar;9(3):e1003419. doi: 0.1371/journal.pgen.1003419. Epub 2013 Mar 28. PMID: 23555315 Mandelker D et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. PMID: 28873162 Maxwell KN et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med. 2015 Aug;17(8):630-8. doi: 10.1038/gim.2014.176. Epub 2014 Dec 11. PubMed PMID:25503501 - |
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 11, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 22, 2024 | - - |
Familial cancer of breast Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Biotechnology, Institute of Science, Nirma University | Jan 30, 2023 | The RAD50c.2647C>T (p.Arg883Cys) is single nucleotide polymorphism, which does not show any effect on the MRE11 and the BRCA1 interactions with RAD50, there by unaffecting the double strand DNA repair damage mechanism. Hence, although the proband has a family history of breast and ovarian cancer in the family and she is also detected with breast and ovarian cancer, yet there is no probable stong correlation of the disease to the muation, and hence has been classified as VUS. - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 21, 2022 | Variant summary: RAD50 c.2647C>T (p.Arg883Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00058 in 251140 control chromosomes in the gnomAD database, including 1 homozygotes. The observed variant frequency is approximately 9 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAD50 causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (6.3e-05), strongly suggesting that the variant is benign. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (benign n=1, likely benign n=2, VUS n=2). Based on the evidence outlined above, the variant was classified as benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
.;.;.;T
Eigen
Uncertain
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;.;.;L
PrimateAI
Uncertain
T
REVEL
Benign
Sift4G
Uncertain
.;.;.;D
Polyphen
1.0
.;.;.;D
Vest4
0.67
MVP
0.67
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at